CytoMed Therapeutics Limited Ordinary Shares
Veridion Score
Composite trend over time
Why is GDTC moving today?
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for GDTC.
GDTC insider activity
CytoMed Therapeutics Limited Ordinary Shares
No multi-insider buying cluster in the last 90 days
Net buying: $129K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-15 | 2026-05-13 | Choo Chee Kong | Insider | buy | $1.15 | 112,000 | 430,324 | $129K | SEC Form 4 |
GDTC contract awards, year to date.
Public federal awards linked to this ticker.
GDTC lobbying filings, year to date.
Registered lobbying filings matched to CytoMed Therapeutics Limited Ordinary Shares.